Skip to main content
Premium Trial:

Request an Annual Quote

InfanDx Initiates Clinical Study for Metabolomic Perinatal Brain Damage Test

NEW YORK (GenomeWeb) – Germany's InfanDx announced it has received the go-ahead from an ethics committee to proceed with a verification study for its metabolomics-based test for brain damage from perinatal asphyxia, or oxygen deficit during birth.

The study, called the Asphyxia-Associated Metabolite Biomarker Investigation (AAMBI) aims to confirm in humans the presence of metabolite profiles found in animal studies that indicated brain damage from asphyxia.

Over the next six months, the firm said it will take post-natal blood samples from 80 newborns suffering from moderate to severe neonatal encephalopathy, as well as healthy controls.

The test could help to quickly diagnose newborns suffering from asphyxia that occurs before, during, or after birth. Earlier diagnosis could push babies towards therapies such as induced hypothermia that must start within six hours after birth.

"This ethics vote and our existing partner clinics featuring sufficient annual case numbers now enable us to take this most meaningful step in our recent company history," InfanDx CEO Ron Meyer said in a statement. 

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.